Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro

Eskiler G. G., ÇEÇENER G., DİKMEN G., EGELİ Ü., TUNCA B.

CURRENT DRUG DELIVERY, cilt.16, sa.6, ss.511-529, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.2174/1567201816666190515105532
  • Dergi Adı: CURRENT DRUG DELIVERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.511-529
  • Anahtar Kelimeler: Triple Negative Breast Cancer (TNBC), PARP inhibitors, Talazoparib (BMN 673), Solid Lipid Nanoparticles (SLNs), Apoptosis, cytotoxic effects, DRUG-DELIVERY-SYSTEMS, INHIBITOR BMN 673, PARP INHIBITOR, DNA-REPAIR, MULTIDRUG-RESISTANCE, SYNTHETIC LETHALITY, HIGHLY POTENT, CANCER, CYTOTOXICITY, PACLITAXEL
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized.